FDA Warns Approval Of BioDelivery's Fentanyl Product Onsolis Is One Of A Kind
This article was originally published in The Pink Sheet Daily
Executive Summary
Onsolis' REMS is no template for long-acting opiates under the agency's classwide requirement, FDA says.